Disruption of iron homeostasis and relevant pharmacotherapies in Alzheimer's disease
10.16438/j.0513-4870.2016-0220
- VernacularTitle:阿尔茨海默病与铁稳态失常及相关药物研发现状
- Author:
Xiang-yu ZHAO
1
;
Yao WANG
1
;
Gui-bin WANG
1
;
Jian-jun ZHANG
1
Author Information
1. Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
- Publication Type:REVIEWS
- Keywords:
Alzheimer's disease;
iron homeostasis;
oxidative stress;
amyloid-β;
apolipoprotein E;
iron chelator
- From:
Acta Pharmaceutica Sinica
2016;51(6):866-
- CountryChina
- Language:Chinese
-
Abstract:
Iron is the most abundant metal element to support the body's physiological activities and play crucial roles in the central nervous system. Iron homeostasis is under strict control in normal circumstances, and some diseases will occur once the homeostasis was disrupted. Numerous researches suggest that iron homeostasis disruptes in Alzheimer's disease (AD) and the homeostasis disruption interacts with AD's hallmarks. Dispute still exists on how iron plays a role in AD despite of the great number of researches. This article will focus on iron metabolism, normal function in the brain and recent therapies of AD based on iron chelation.
